Guido Oelkers - Swedish Orphan President CEO
| BIOVF Stock | USD 29.99 0.29 0.98% |
CEO
Dr. Guido Oelkers, Ph.D. was appointed President and Chief Executive Officer at Swedish Orphan Biovitrum AB, effective as of May 22, 2017. He holds PhD in Strategic Management, University of South Australia, Master of Economics, South Bank University, London, Complementary studies in Economics, London School of Economics and Political Science. He is Chairman of the Advisory Committee of Zentiva Group, Industrial Advisor EQT. Previously, he was CEO BSN Medical, President CEO Gambro, EVP Commercial Operations Nycomed, CEO Invida, Global Head of Healthcare DKSH, previous managerial roles at Aventis and preceding entities, member of the Board of Directors at Meda and Sartorius AG. since 2017.
| Age | 58 |
| Tenure | 8 years |
| Phone | 46 86 97 20 00 |
| Web | https://www.sobi.com |
Swedish Orphan Management Efficiency
The company has return on total asset (ROA) of 0.0555 % which means that it generated a profit of $0.0555 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1061 %, meaning that it generated $0.1061 on every $100 dollars invested by stockholders. Swedish Orphan's management efficiency ratios could be used to measure how well Swedish Orphan manages its routine affairs as well as how well it operates its assets and liabilities.Swedish Orphan Biovitrum has accumulated 8.78 B in total debt with debt to equity ratio (D/E) of 0.41, which is about average as compared to similar companies. Swedish Orphan Biovitrum has a current ratio of 1.0, suggesting that it is in a questionable position to pay out its financial obligations in time and when they become due. Debt can assist Swedish Orphan until it has trouble settling it off, either with new capital or with free cash flow. So, Swedish Orphan's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Swedish Orphan Biovitrum sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Swedish to invest in growth at high rates of return. When we think about Swedish Orphan's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 14 records | CEO Age | ||
| Mark Strobeck | Rockwell Medical | 54 | |
| Nikhil Lalwani | ANI Pharmaceuticals | 47 | |
| Paul Josephs | Lifecore Biomedical | 60 | |
| James Hall | Lifecore Biomedical | 62 | |
| Vikram Karnani | Collegium Pharmaceutical | 50 | |
| David RPh | Evoke Pharma | 60 | |
| Milan Kalawadia | Dr Reddys Laboratories | N/A | |
| M Ramana | Dr Reddys Laboratories | 52 | |
| David Gonyer | Evoke Pharma | 60 | |
| Frank Lee | Pacira BioSciences, | 57 | |
| MARC KIKUCHI | Dr Reddys Laboratories | 51 | |
| Venkata MBA | Dr Reddys Laboratories | 56 | |
| David Moatazedi | Evolus Inc | 47 | |
| Patrick Aghanian | Dr Reddys Laboratories | 55 | |
Management Performance
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0555 |
Swedish Orphan Biovitrum Leadership Team
Elected by the shareholders, the Swedish Orphan's board of directors comprises two types of representatives: Swedish Orphan inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Swedish. The board's role is to monitor Swedish Orphan's management team and ensure that shareholders' interests are well served. Swedish Orphan's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Swedish Orphan's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Konstantina Karampela, Director Operations | ||
| Christine Wesstrom, Head Operations | ||
| Guido Oelkers, President CEO | ||
| Thomas Larsen, Head Relations | ||
| Pablo Mora, Head Access | ||
| Armin MD, Head Affairs | ||
| Philip Wood, Head of Haemophilia | ||
| Torbjrn Hallberg, G HR | ||
| Daniel Rankin, Head Devel | ||
| Anders MD, Head Officer | ||
| Henrik Stenqvist, Chief Officer |
Swedish Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Swedish Orphan a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0555 | |||
| Profit Margin | 0.14 % | |||
| Current Valuation | 7.05 B | |||
| Shares Outstanding | 295.99 M | |||
| Shares Owned By Insiders | 4.00 % | |||
| Shares Owned By Institutions | 70.55 % | |||
| Price To Earning | 20.33 X | |||
| Price To Book | 2.58 X | |||
| Price To Sales | 3.68 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Swedish Pink Sheet
Swedish Orphan financial ratios help investors to determine whether Swedish Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Swedish with respect to the benefits of owning Swedish Orphan security.